Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBT: 2010-2024

Historic EBT for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$95.1 million.

  • Altimmune's EBT rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.7 million, marking a year-over-year increase of 18.17%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
  • Latest data reveals that Altimmune reported EBT of -$95.1 million as of FY2024, which was down 7.53% from -$88.4 million recorded in FY2023.
  • Altimmune's EBT's 5-year high stood at -$54.5 million during FY2020, with a 5-year trough of -$97.1 million in FY2021.
  • Its 3-year average for EBT is -$89.5 million, with a median of -$88.4 million in 2023.
  • As far as peak fluctuations go, Altimmune's EBT plummeted by 164.65% in 2020, and later increased by 12.55% in 2022.
  • Altimmune's EBT (Yearly) stood at -$54.5 million in 2020, then crashed by 78.27% to -$97.1 million in 2021, then increased by 12.55% to -$84.9 million in 2022, then decreased by 4.17% to -$88.4 million in 2023, then fell by 7.53% to -$95.1 million in 2024.